Interleukin 2 immune response generating formulation, used for treating cancer, comprises IL 2 coupled to transport protein, monoclonal anti IL 2 antibody or monoclonal anti CD 25 antibody
NOVELTY - A formulation comprising one or more components chosen from interleukin (IL)-2 or a derivative thereof coupled to a transport protein, a monoclonal anti-IL-2 antibody, a cancer vaccine based on specific antigens of tumors or tumor growth factors or a monoclonal anti-CD25 antibody, is new. USE - The formulations are used to produce drugs for inducing an anti-IL-2 immune response capable of inhibiting the growth of tumors in cancer patients (claimed). ADVANTAGE - Auto-antibodies which block binding of IL-2 to its receptor are induced and inhibit tumor growth. DETAILED DESCRIPTION - A therapeutic formulation capable of generating an immune response to Interleukin 2 (IL-2), used for treating cancer patients, comprises at least one component chosen from: (a) IL-2 or a derivative thereof coupled to a transport protein genetically or by chemical bonding, as well as a suitable adjuvant; (b) a monoclonal anti-IL-2 antibody; (c) a cancer vaccine based on specific antigens of tumors or tumor growth factors; or (d) a monoclonal anti-CD25 antibody.
40122436
Alternative title(s) : (de) Immuntherapeutische formulierungen mit der fähigkeit, interleukin-2 zu neutralisieren (fr) Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2 (en) Immunotherapeutic formulations with interleukin-2-neutralising capacity
Patent number | Country code | Kind code | Date issued |
MY162106 | MY | A | 2017-05-31 |
EP2112160 | EP | B1 | 2015-07-08 |
TWI433853 | TW | B | 2014-04-11 |
CA2588573 | CA | C | 2013-12-31 |
JP5227028 | JP | B2 | 2013-07-03 |
KR101240457 | KR | B1 | 2013-03-08 |
CN101061136 | CN | B | 2012-12-05 |
AU2005306186 | AU | B2 | 2012-05-31 |
AT525393 | AT | T | 2011-10-15 |
EP1829893 | EP | B1 | 2011-09-21 |
GEP20105039 | GE | B | 2010-07-12 |
EP2112160 | EP | A3 | 2010-01-13 |
US2009274647 | US | A1 | 2009-11-05 |
EP2112160 | EP | A2 | 2009-10-28 |
EA012072 | EA | B1 | 2009-08-28 |
TNSN07187 | TN | A1 | 2008-11-21 |
BRPI0518007 | BR | A | 2008-10-21 |
HK1113374 | HK | A1 | 2008-10-03 |
CU23297 | CU | A1 | 2008-07-24 |
JP2008526686 | JP | A | 2008-07-24 |
ZA200703528 | ZA | B | 2008-06-25 |
EA200701071 | EA | A1 | 2007-12-28 |
MA29044 | MA | B1 | 2007-11-01 |
CN101061136 | CN | A | 2007-10-24 |
EP1829893 | EP | A1 | 2007-09-05 |
CR9097 | CR | A | 2007-08-28 |
KR20070084025 | KR | A | 2007-08-24 |
TR200704213 | TR | T2 | 2007-08-21 |
MX2007005808 | MX | A | 2007-07-20 |
AR051494 | AR | A1 | 2007-01-17 |
PE20061172 | PE | A1 | 2006-12-16 |
TW200631591 | TW | A | 2006-09-16 |
SG122897 | SG | A1 | 2006-06-29 |
AU2005306186 | AU | A1 | 2006-05-26 |
CA2588573 | CA | A1 | 2006-05-26 |
WO2006053508 | WO | A1 | 2006-05-26 |